Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSDNASDAQ:CYADNASDAQ:GEMPOTCMKTS:HBPCFNASDAQ:NBSE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.82+2.0%$0.82$0.70▼$1.65$63.12M2.05361,598 shs27,100 shsCYADCelyad$0.60$0.67$0.46▼$3.07N/AN/AN/A3,009 shsGEMPGemphire Therapeutics$0.65-2.1%$4.97$0.24▼$1.49$9.64M2.82127,174 shs48,968 shsHBPCFHelix Biopharma$0.60$0.60$0.59▼$0.60$31.81M-0.131 shsN/ANBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%+6.75%+6.06%-4.53%-34.24%CYADCelyad0.00%0.00%0.00%0.00%0.00%GEMPGemphire Therapeutics0.00%+2.84%-5.68%-55.62%-86.16%HBPCFHelix Biopharma0.00%0.00%0.00%+31.90%+335.73%NBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLSDClearside Biomedical1.4179 of 5 stars3.53.00.00.00.60.00.0CYADCelyadN/AN/AN/AN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 3.00Buy$4.75477.86% UpsideCYADCelyad 0.00N/AN/AN/AGEMPGemphire Therapeutics 0.00N/AN/AN/AHBPCFHelix Biopharma 0.00N/AN/AN/ANBSENeuBase Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CYAD, CLSD, GEMP, HBPCF, and NBSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $5.005/16/2025CLSDClearside BiomedicalJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.005/15/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$4.00 ➝ $3.004/8/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$3.76M16.97N/AN/A($0.51) per share-1.61CYADCelyad$200K79.56N/AN/A$0.02 per share30.00GEMPGemphire TherapeuticsN/AN/AN/AN/A$0.54 per shareN/AHBPCFHelix BiopharmaN/AN/AN/AN/A($0.02) per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$0.41N/AN/AN/A-818.57%N/A-114.23%8/11/2025 (Estimated)CYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AGEMPGemphire Therapeutics-$23.64MN/A0.00∞N/AN/A-419.70%-173.05%N/AHBPCFHelix Biopharma-$6.82M-$0.14N/A∞N/AN/AN/A-747.46%N/ANBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/ALatest CYAD, CLSD, GEMP, HBPCF, and NBSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/16/2025Q3 2025HBPCFHelix BiopharmaN/A-$0.02N/A-$0.02N/AN/A5/14/2025Q1 2025CLSDClearside Biomedical-$0.12-$0.11+$0.01-$0.11$0.20 million$2.33 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AGEMPGemphire TherapeuticsN/AN/AN/AN/AN/AHBPCFHelix BiopharmaN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.193.19CYADCelyad1.492.292.14GEMPGemphire TherapeuticsN/A0.670.67HBPCFHelix BiopharmaN/A0.420.99NBSENeuBase TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%CYADCelyadN/AGEMPGemphire Therapeutics17.53%HBPCFHelix BiopharmaN/ANBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.20%CYADCelyad0.94%GEMPGemphire Therapeutics22.70%HBPCFHelix Biopharma7.60%NBSENeuBase Therapeutics7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical3077.71 million72.89 millionOptionableCYADCelyad9526.52 million26.28 millionNot OptionableGEMPGemphire Therapeutics914.87 millionN/ANot OptionableHBPCFHelix Biopharma953.02 million48.99 millionNot OptionableNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionableCYAD, CLSD, GEMP, HBPCF, and NBSE HeadlinesRecent News About These CompaniesGreenlight Capital Q3 2024 LetterOctober 17, 2024 | seekingalpha.comNeuBase Therapeutics shareholder meeting adjourns without dissolution approvalMay 13, 2024 | bizjournals.comNeuBase Therapeutics to delist from Nasdaq next weekMay 6, 2024 | bizjournals.comNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 6, 2024 | finanznachrichten.deNeuBase Therapeutics Announces Receipt of Notice from NasdaqApril 5, 2024 | globenewswire.comOnce-promising Pittsburgh biotech firm shutting down for goodMarch 27, 2024 | technical.lyTWhy Neubase Therapeutics (NBSE) Shares Are NosedivingMarch 27, 2024 | msn.comNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversMarch 26, 2024 | msn.comWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?March 26, 2024 | investorplace.comNeuBase Therapeutics sets shareholder meeting on dissolution planMarch 25, 2024 | bizjournals.comNeuBase Therapeutics IncFebruary 26, 2024 | edition.cnn.comNeuBase Therapeutics, Inc. (NBSE)February 20, 2024 | finance.yahoo.comNeuBase Therapeutics Inc (O7P.BE)January 19, 2024 | ca.finance.yahoo.comMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsJanuary 1, 2024 | knoxdaily.comKCMU halts licensing agreement with NeuBase TherapeuticsDecember 22, 2023 | bizjournals.comPsychemedics Corporation Appoints Daniella Mehalik as VP - FinanceNovember 27, 2023 | finance.yahoo.comNeuBase Therapeutics Inc NBSENovember 6, 2023 | morningstar.comMNeuBase Therapeutics: Other EventsOctober 21, 2023 | cbonds.comCNeuBase Therapeutics, Inc. (NBSE.MX)October 6, 2023 | finance.yahoo.comNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. WainwrightSeptember 20, 2023 | knoxdaily.comKNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYAD, CLSD, GEMP, HBPCF, and NBSE Company DescriptionsClearside Biomedical NASDAQ:CLSD$0.82 +0.02 (+1.99%) Closing price 07/3/2025 03:14 PM EasternExtended Trading$0.82 0.00 (-0.24%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Celyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Gemphire Therapeutics NASDAQ:GEMPGemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.Helix Biopharma OTCMKTS:HBPCF$0.60 0.00 (0.00%) As of 07/3/2025Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.NeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
